Biogen loses CMO, neuromuscular leader; John Hood adds president, CFO at Endeavor BioMedicines

Maha Radhakrishnan

Biogen chief medical officer Maha Radhakrishnan is out after four years “as of March 1,” a spokesperson tells Peer Review. Biogen didn’t draw up a press release for her departure, but a board appointment at NYSE newcomer Alto Neuroscience was the first indication that Radhakrishnan decided to leave. In her second time around at the big biotech, the Alzheimer’s drug Aduhelm flamed out, while the Eisai-partnered follow-up Leqembi earned a full FDA approval as Eli Lilly waits on the sidelines with donanemab. From 2013-16, Radhakrishnan was Biogen’s VP, US medical and VP, Europe and Canada medical before her tenure at Bioverativ and Sanofi. “Maha made many important contributions to Biogen and the patients we serve — most notably establishing our framework for early patient access, enabling many patients to benefit from important and potentially lifesaving new therapies globally,”…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks